Skip to main content

and
  1. Article

    Open Access

    Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses

    Costs of informal care are ignored in many cost-effectiveness analyses (CEAs) conducted from a societal perspective; however, these costs are relevant for lifesaving interventions targeted at the older populat...

    Saskia de Groot, Irene Santi, Pieter Bakx, Bram Wouterse in PharmacoEconomics (2023)

  2. Article

    Open Access

    Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines

    In the drive towards faster patient access to treatments, health technology assessment (HTA) agencies are increasingly faced with reliance on evidence from surrogate endpoints, leading to increased decision un...

    Bogdan Grigore, Oriana Ciani, Florian Dams, Carlo Federici in PharmacoEconomics (2020)

  3. Article

    Open Access

    Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    The National Institute for Health and Care Excellence, as part of the institute’s single technology appraisal process, invited the manufacturer of ribociclib (Kisqali®, Novartis) to submit evidence regarding the ...

    Nasuh C. Büyükkaramikli, Saskia de Groot, Rob Riemsma, Debra Fayter in PharmacoEconomics (2019)

  4. Article

    Open Access

    Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

    The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the manufacturer of pomalidomide (POM; Imnovid®, Celgene) to submit evid...

    Nasuh C. Büyükkaramikli, Saskia de Groot, Debra Fayter, Robert Wolff in PharmacoEconomics (2018)

  5. No Access

    Article

    Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence

    Previous cost-effectiveness analyses of oxaliplatin have been based on randomised trials whereas current Dutch policy requires evidence from daily practice. The objective of this study was to examine the real-...

    Chantal W. M. van Gils, Saskia de Groot, William K. Redekop in PharmacoEconomics (2013)

  6. Article

    Open Access

    Investigating selection on viruses: a statistical alignment approach

    Two problems complicate the study of selection in viral genomes: Firstly, the presence of genes in overlap** reading frames implies that selection in one reading frame can bias our estimates of neutral mutat...

    Saskia de Groot, Thomas Mailund, Gerton Lunter, Jotun Hein in BMC Bioinformatics (2008)